Login to Your Account

Clinic Roundup

Friday, September 7, 2012

• Durata Therapeutics Inc., of Morristown, N.J., completed target enrollment of 556 patients in DISCOVER 1 (Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response), one of two ongoing, global, Phase III trials of lead candidate dalbavancin in acute bacterial skin and skin structure infections (abSSSI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription